✦ LIBER ✦

Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy

✍ Scribed by Hannemann, J; Kristel, P; van Tinteren, H; Bontenbal, M; van Hoesel, Q G C M; Smit, W M; Nooij, M A; Voest, E E; van der Wall, E; Hupperets, P

Book ID: 109998992
Publisher: Nature Publishing Group
Year: 2006
Tongue: English
Weight: 166 KB
Volume: 95
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6603449

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Topoisomerase IIα expression rather than

Topoisomerase IIα expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer

✍ Christian Schindlbeck; D. Mayr; C. Olivier; B. Rack; V. Engelstaedter; J. Juecks 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 551 KB

Racial Disparity in the Dose and Dose In

Racial Disparity in the Dose and Dose Intensity of Breast Cancer Adjuvant Chemotherapy

✍ Jennifer J. Griggs; Melony E.S. Sorbero; Azadeh T. Stark; Susanne E. Heininger; 📂 Article 📅 2003 🏛 Springer US 🌐 English ⚖ 128 KB

Characterization of topoisomerase IIα ge

Characterization of topoisomerase IIα gene amplification and deletion in breast cancer

✍ Tero A.H. Järvinen; Minna Tanner; Maarit Bärlund; Åke Borg; Jorma Isola 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 311 KB 👁 1 views

Topoisomerase II␣ (TOP2A) is a key enzyme in DNA replication and a molecular target for many important anticancer drugs. TOP2A is amplified or deleted together with amplification of the closely located ERBB2/HER-2/neu oncogene in breast cancer. We characterized the copy number aberrations of TOP2A a

Role of adjuvant chemotherapy in male br

Role of adjuvant chemotherapy in male breast cancer

✍ Helen Z. Patel II; Aman U. Buzdar; Gabriel N. Hortobagyi 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 287 KB 👁 3 views

Amplification and Deletion of Topoisomer

Amplification and Deletion of Topoisomerase IIα Associate with ErbB-2 Amplification and Affect Sensitivity to Topoisomerase II Inhibitor Doxorubicin in Breast Cancer

✍ Tero A.H. Järvinen; Minna Tanner; Virpi Rantanen; Maarit Bärlund; Åke Borg; Seij 📂 Article 📅 2000 🏛 American Society for Investigative Pathology 🌐 English ⚖ 1010 KB

Variations in Dose and Dose Intensity of

Variations in Dose and Dose Intensity of Adjuvant CMF Chemotherapy for Breast Cancer Throughout the UK

✍ R.S.D. Brown; R.J. Burcombe; M.E. Osborne; M.N. Gaze 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 154 KB